Valuation: Astellas Pharma Inc.

Market Cap 4,280B 26.92B 23.06B 21.58B 19.75B 37.07B 2,576B 37.56B 255B 99.42B 1,294B 101B 98.89B P/E 2027 *
11.6x
P/E 2028 * 12.3x
Enterprise Value 4,238B 26.66B 22.84B 21.37B 19.56B 36.71B 2,551B 37.19B 252B 98.44B 1,281B 100B 97.92B EV / Sales 2027 *
1.83x
EV / Sales 2028 * 1.8x
Free-Float
98.88%
Yield 2027 *
3.36%
Yield 2028 * 3.47%
1 day+0.61%
1 week+2.26%
Current month+9.63%
1 month+10.68%
3 months+4.31%
6 months-5.69%
Current year+13.26%
1 week 14.26
Extreme 14.26
15.18
1 month 13.04
Extreme 13.043
15.18
Current year 12.82
Extreme 12.8175
17.35
1 year 10.03
Extreme 10.03
17.35
3 years 8.37
Extreme 8.37
17.35
5 years 8.37
Extreme 8.37
18.18
10 years 8.37
Extreme 8.37
18.46
Manager TitleAgeSince
Chief Executive Officer 63 2023-02-09
Director of Finance/CFO 54 2023-10-31
Compliance Officer - 2025-03-31
Director TitleAgeSince
Chairman 66 2023-02-09
Director/Board Member 63 2019-05-31
Director/Board Member 58 2023-05-31
Change 5-day change 1-year change 3-year change Capi.($)
+0.61%+2.26% - - 27.31B
+1.55%+7.31%+78.41%+130.23% 1,109B
+1.53%+4.26%+51.70%+62.20% 644B
+1.45%+6.45%+26.76%+76.85% 463B
+1.02%+5.77%+43.09%+47.70% 371B
+0.85%+4.07%+23.88%+41.58% 301B
+1.26%+6.81%+1.59%+14.67% 256B
+1.64%+5.77%+48.49%+68.45% 234B
+1.59%+2.09%-15.52%-52.29% 205B
+2.73%+6.59%+26.98%+94.21% 178B
Average +1.41%+3.00%+31.71%+53.73% 417.9B
Weighted average by Cap. +1.46%+3.26%+45.00%+73.42%

Financials

2027 *2028 *
Net sales 2,315B 14.57B 12.48B 11.67B 10.69B 20.05B 1,394B 20.32B 138B 53.79B 700B 54.69B 53.5B 2,137B 13.44B 11.51B 10.77B 9.86B 18.5B 1,286B 18.75B 127B 49.63B 646B 50.46B 49.37B
Net income 356B 2.24B 1.92B 1.79B 1.64B 3.08B 214B 3.12B 21.2B 8.27B 108B 8.4B 8.22B 333B 2.09B 1.79B 1.68B 1.53B 2.88B 200B 2.92B 19.81B 7.72B 101B 7.85B 7.68B
Net Debt -41.87B -263M -226M -211M -193M -363M -25.2B -367M -2.49B -973M -12.66B -989M -968M -439B -2.76B -2.37B -2.21B -2.03B -3.8B -264B -3.85B -26.15B -10.2B -133B -10.37B -10.14B
Logo Astellas Pharma Inc.
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
Employees
14,099
Date Price Change Volume
26-08-21 $15.05 +0.60% 60,969
26-08-20 $14.96 -0.99% 185,962
26-08-19 $15.11 +4.79% 178,364
26-08-18 $14.42 +0.63% 83,689
26-08-17 $14.33 -2.65% 92,840
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
2,387.00JPY
Average target price
2,476.43JPY
Spread / Average Target
+3.75%

Quarterly revenue - Rate of surprise